Mar. 11, 2024
MONTPELLIER, FRANCE — Biotechnology company Sensorion has announced that it has met the primary endpoint for its Phase 2a clinical trial of SENS-401, a drug candidate aimed at preserving residual hearing after cochlear implantation. The Phase 2a trial was a multicenter, randomized, controlled, open-label study designed to evaluate the presence of SENS-401 in the inner ear fluid (perilymph) at potentially